6-chloro-4-(3-methoxyphenyl)-4-propyl-3-(2,2,2-trifluoroethyl)-1H-quinazolin-2-one | 1250437-40-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6-chloro-4-(3-methoxyphenyl)-4-propyl-3-(2,2,2-trifluoroethyl)-1H-quinazolin-2-one
• CAS: 1250437-40-1
• 化学式: C₂₀H₂₀ClF₃N₂O₂
• 分子量: 412.839
• InChiKey: VRUQXMBWFAQQFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  、 丙基溴化镁 在 氯化亚砜 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 6-chloro-4-(3-methoxyphenyl)-4-propyl-3-(2,2,2-trifluoroethyl)-1H-quinazolin-2-one
  参考文献：
  名称：

  Discovery and expanded SAR of 4,4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonists

  摘要：

  The discovery and synthesis of 4,4-disubstituted quinazolinones as T-type calcium channel antagonists is reported. Based on lead compounds 2 and 3, a focused SAR campaign driven by the optimization of potency, metabolic stability, and pharmacokinetic profile identified 45 as a potent T-type Ca2+ channel antagonist with minimized PXR activation. In vivo, 45 suppressed seizure frequency in a rat model of absence epilepsy and showed significant alterations of sleep architecture after oral dosing to rats as measured by EEG. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.010

文献信息

• Discovery and expanded SAR of 4,4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonists
  作者：Kelly-Ann S. Schlegel、Zhi-Qiang Yang、Thomas S. Reger、Youheng Shu、Rowena Cube、Kenneth E. Rittle、Phung Bondiskey、Mark G. Bock、George D. Hartman、Cuyue Tang、Jeanine Ballard、Yuhsin Kuo、Thomayant Prueksaritanont、Cindy E. Nuss、Scott M. Doran、Steven V. Fox、Susan L. Garson、Richard L. Kraus、Yuxing Li、Victor N. Uebele、John J. Renger、James C. Barrow

  DOI：10.1016/j.bmcl.2010.07.010

  日期：2010.9

  The discovery and synthesis of 4,4-disubstituted quinazolinones as T-type calcium channel antagonists is reported. Based on lead compounds 2 and 3, a focused SAR campaign driven by the optimization of potency, metabolic stability, and pharmacokinetic profile identified 45 as a potent T-type Ca2+ channel antagonist with minimized PXR activation. In vivo, 45 suppressed seizure frequency in a rat model of absence epilepsy and showed significant alterations of sleep architecture after oral dosing to rats as measured by EEG. (C) 2010 Elsevier Ltd. All rights reserved.